Cargando…
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
The pharmacotherapy of inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) has experienced significant progress with the advent of monoclonal antibodies (mABs). As therapeutic proteins, mABs display peculiar pharmacokinetic characteristics that differentiate them from chemical drugs...
Autores principales: | Di Paolo, Antonello, Luci, Giacomo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898166/ https://www.ncbi.nlm.nih.gov/pubmed/33628180 http://dx.doi.org/10.3389/fphar.2020.610806 |
Ejemplares similares
-
Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021) -
Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine
por: Micaglio, Emanuele, et al.
Publicado: (2021) -
Pharmacogenetics of anticancer monoclonal antibodies
por: Shek, Dmitrii, et al.
Publicado: (2019) -
Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies
por: Yamamoto-Furusho, Jesús K
Publicado: (2017) -
Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
por: Haustrate, Aurélien, et al.
Publicado: (2019)